Questionable recommendation for LPS for IVF/ICSI in ESHRE guideline 2019: ovarian stimulation for IVF/ICSI.
作者信息
Piette Paul C M
机构信息
Pharm D, Head of Scientific & Medical Affairs, Besins Healthcare Global, Le Concorde, 11 rue du Gabian, 98000 Monaco.
出版信息
Hum Reprod Open. 2021 Mar 3;2021(1):hoab005. doi: 10.1093/hropen/hoab005. eCollection 2021.
Abstract
摘要
相似文献
1
Questionable recommendation for LPS for IVF/ICSI in ESHRE guideline 2019: ovarian stimulation for IVF/ICSI.2019年ESHRE指南中关于体外受精/卵胞浆内单精子注射使用脂多糖的可疑推荐：体外受精/卵胞浆内单精子注射的卵巢刺激。
Hum Reprod Open. 2021 Mar 3;2021(1):hoab005. doi: 10.1093/hropen/hoab005. eCollection 2021.
2
Reply: Questionable recommendation for LPS for IVF/ICSI in ESHRE guideline 2019: ovarian stimulation for IVF/ICSI.回复：2019年欧洲人类生殖与胚胎学会（ESHRE）指南中关于体外受精/卵胞浆内单精子注射（IVF/ICSI）使用脂多糖（LPS）的可疑推荐：IVF/ICSI的卵巢刺激。
Hum Reprod Open. 2021 Mar 3;2021(1):hoab006. doi: 10.1093/hropen/hoab006. eCollection 2021.
3
ICSI does not improve reproductive outcomes in autologous ovarian response cycles with non-male factor subfertility.ICSI 并不能改善非男性因素导致的卵巢反应不良的自身免疫性不育患者的妊娠结局。
Hum Reprod. 2020 Mar 27;35(3):583-594. doi: 10.1093/humrep/dez301.
4
Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI.勘误：ESHRE指南：体外受精/卵胞浆内单精子注射的卵巢刺激。
Hum Reprod Open. 2020 Dec 29;2020(4):hoaa067. doi: 10.1093/hropen/hoaa067. eCollection 2020.
5
Assisted reproductive technology in Europe, 2011: results generated from European registers by ESHRE.2011年欧洲辅助生殖技术：欧洲人类生殖与胚胎学会（ESHRE）欧洲登记处发布的结果
Hum Reprod. 2016 Feb;31(2):233-48. doi: 10.1093/humrep/dev319. Epub 2016 Jan 5.
6
ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE).ART 在欧洲，2014：ESHRE 欧洲注册处产生的结果：欧洲人类生殖与胚胎学学会（ESHRE）的欧洲 IVF 监测联合组织（EIM）。
Hum Reprod. 2018 Sep 1;33(9):1586-1601. doi: 10.1093/humrep/dey242.
7
Secondary sex ratio in assisted reproduction: an analysis of 1 376 454 treatment cycles performed in the UK.辅助生殖中的第二性征比例：对英国进行的1376454个治疗周期的分析。
Hum Reprod Open. 2019 Oct 5;2019(4):hoz020. doi: 10.1093/hropen/hoz020. eCollection 2019.
8
Clinical implications of sperm DNA damage in IVF and ICSI: updated systematic review and meta-analysis.体外受精和卵胞浆内单精子注射中精子 DNA 损伤的临床意义：更新的系统评价和荟萃分析。
Biol Rev Camb Philos Soc. 2021 Aug;96(4):1284-1300. doi: 10.1111/brv.12700. Epub 2021 Mar 1.
9
Biopsying, fragmentation and autotransplantation of fresh ovarian cortical tissue in infertile women with diminished ovarian reserve.对卵巢储备功能下降的不孕妇女进行新鲜卵巢皮质组织活检、分割和自体移植。
Hum Reprod. 2019 Oct 2;34(10):1924-1936. doi: 10.1093/humrep/dez152.
10
Assisted reproductive technology in Europe, 2009: results generated from European registers by ESHRE.欧洲 2009 年辅助生殖技术：ESHRE 欧洲注册中心获得的结果。
Hum Reprod. 2013 Sep;28(9):2318-31. doi: 10.1093/humrep/det278. Epub 2013 Jul 9.
引用本文的文献
1
Comparison of oral dydrogesterone and vaginal progesterone for luteal phase support in natural and modified natural cycle frozen embryo transfers.口服地屈孕酮与阴道用黄体酮在自然周期和改良自然周期冻融胚胎移植中黄体期支持作用的比较
J Ovarian Res. 2025 Aug 14;18(1):183. doi: 10.1186/s13048-025-01765-5.
2
Perinatal complications and neonatal outcomes in fertilization/intracytoplasmic sperm injection: a propensity score matching cohort study.受精/卵胞浆内单精子注射的围产期并发症和新生儿结局：倾向评分匹配队列研究。
Front Endocrinol (Lausanne). 2024 Jul 18;15:1405550. doi: 10.3389/fendo.2024.1405550. eCollection 2024.
3
Reply: Questionable recommendation for LPS for IVF/ICSI in ESHRE guideline 2019: ovarian stimulation for IVF/ICSI.回复：2019年欧洲人类生殖与胚胎学会（ESHRE）指南中关于体外受精/卵胞浆内单精子注射（IVF/ICSI）使用脂多糖（LPS）的可疑推荐：IVF/ICSI的卵巢刺激。
Hum Reprod Open. 2021 Mar 3;2021(1):hoab006. doi: 10.1093/hropen/hoab006. eCollection 2021.
本文引用的文献
1
Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI.勘误：ESHRE指南：体外受精/卵胞浆内单精子注射的卵巢刺激。
Hum Reprod Open. 2020 Dec 29;2020(4):hoaa067. doi: 10.1093/hropen/hoaa067. eCollection 2020.
2
Delayed Fulminant Hepatic Failure from Dydrogesterone-Related In Vitro Fertilization Therapy Requiring Liver Transplantation During Pregnancy.与地屈孕酮相关的体外受精治疗导致的延迟性暴发性肝衰竭，孕期需进行肝移植
Am J Case Rep. 2020 Sep 17;21:e925690. doi: 10.12659/AJCR.925690.
3
Fetal safety of medications used in treating infertility.治疗不孕症药物的胎儿安全性。
Expert Rev Clin Pharmacol. 2020 Sep;13(9):991-1000. doi: 10.1080/17512433.2020.1803738. Epub 2020 Oct 3.
4
Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques.在辅助生殖技术中使用地屈孕酮进行黄体期支持的活产率和安全性概况。
Singapore Med J. 2017 Jun;58(6):294-297. doi: 10.11622/smedj.2016080. Epub 2016 Apr 19.
5
The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy.孕早期口服地屈孕酮对胎儿心脏发育的影响。
Pediatr Cardiol. 2015 Oct;36(7):1483-8. doi: 10.1007/s00246-015-1190-9. Epub 2015 May 15.
Zotero 插件